Preclinical In Vivo Evaluation of the Safety of a Multi-shRNA-based Gene Therapy Against HIV-1
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Highly active antiretroviral therapy (HAART) has significantly improved the quality of life and the life expectancy of HIV-infected individuals. Still, drug-induced side effects and emergence of drug-resistant viral variants remain important issues that justify the exploration of alternative therapeutic options. One strategy consists of a gene therapy based on RNA interference to induce the sequence-specific degradation of the HIV-1 RNA genome. We have selected four potent short hairpin RNA (shRNA) candidates targeting the viral capside, integrase, protease and tat/rev open-reading frames and screened the safety of them during human hematopoietic cell development, both in vitro and in vivo. Although the four shRNA candidates appeared to be safe in vitro, one shRNA candidate impaired the in vivo development of the human immune system in Balb/c Rag2(-/-)IL-2Rγc(-/-) (BRG) mice. The three remaining shRNA candidates were combined into one single lentiviral vector (LV), and safety of the shRNA combination during human hematopoietic cell development was confirmed. Overall, we demonstrate here the preclinical in vivo safety of a LV expressing three shRNAs against HIV-1, which is proposed for a future Phase I clinical trial.Molecular Therapy-Nucleic Acids (2013) 2, e120; doi:10.1038/mtna.2013.48; published online 3 September 2013.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341
Siliciano, J. D., Kajdas, J., Finzi, D., Quinn, T. C., Chadwick, K., Margolick, J. B., Kovacs, C., Gange, S. J., & Siliciano, R. F. (2003) · Nature Medicine · doi:10.1038/nm880 · Cited by 1,703
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Legrand, N., Cupedo, T., van Lent, A. U., Ebeli, M. J., Weijer, K., Hanke, T., & Spits, H. (2006) · Blood · doi:10.1182/blood-2006-01-0190 · Cited by 82
Self-citationCentlivre, M., Zhou, X., Pouw, S. M., Weijer, K., Kleibeuker, W., Das, A. T., Blom, B., Seppen, J., Berkhout, B., & Legrand, N. (2010) · Gene Therapy · doi:10.1038/gt.2009.109 · Cited by 30
Self-citation
Cited by
APOBEC Enzymes as Targets for Virus and Cancer Therapy
Olson, M. E., Harris, R. S., & Harki, D. A. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.10.007 · Cited by 164
Multifunctional "core-shell" nanoparticles-based gene delivery for treatment of aggressive melanoma
Li, L., Song, L., Yang, X., Li, X., Wu, Y., He, T., Wang, N., Yang, S., Zeng, Y., Yang, L., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.019 · Cited by 62
“It has great potential to treat a variety of diseases, such as cystic fibrosis, genetic diseases and cardiovascular diseases [1-3].”
BackgroundPromoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing
Suzuki, K., Hattori, S., Marks, K., Ahlenstiel, C., Maeda, Y., Ishida, T., Millington, M., Boyd, M., Symonds, G., Cooper, D. A., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.64 · Cited by 61
van der Velden, Y. U., Kleibeuker, W., Harwig, A., Klaver, B., Siteur-van Rijnstra, E., Frankin, E., Berkhout, B., & Das, A. T. (2016) · Virology · doi:10.1016/j.virol.2015.11.004 · Cited by 3
Self-citation
Metadata
- Authors
- Centlivre, M., Legrand, N., Klamer, S., Liu, Y. P., Eije, K. J. V., Bohne, M., Rijnstra, E. S.-V., Weijer, K., Blom, B., Voermans, C., Spits, H., & Berkhout, B.
- Venue
- Molecular Therapy - Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2013
- Volume
- 2
- Pages
- e120
- ISSN
- 2162-2531 (ISSN-L)
- OpenAlex
- W1966858164
- Cited by
- 52
- References
- 5
- FWCI
- 5.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.